Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forty Seven

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

Gilead Sciences

Gilead gets EU nod for cancer drug Zydelig

Approved for patients with chronic lymphocytic leukaemia and follicular lymphoma

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links